Best Medications for Long-Term Benefit in Type 2 Diabetes

Primary Medication Selection Based on Comorbidities

The American Diabetes Association recommends initiating a GLP-1 receptor agonist with proven cardiovascular benefit, such as semaglutide, liraglutide, or dulaglutide, in patients with established cardiovascular disease, independent of current A1C or metformin use, as these agents reduce major adverse cardiovascular events by 13-26% 1, 3
The American College of Cardiology suggests using an SGLT2 inhibitor with cardiovascular benefit, such as empagliflozin, canagliflozin, or dapagliflozin, if GLP-1 receptor agonists are not tolerated, as SGLT2 inhibitors reduce cardiovascular events by 12-26% and provide complementary protection when combined with GLP-1 receptor agonists 1, 2
The American Heart Association notes that the cardiovascular benefits of GLP-1 receptor agonists and SGLT2 inhibitors occur independent of A1C lowering, meaning they should be initiated even if glycemic targets are already met 1

The American Diabetes Association recommends targeting an A1C of <7% to reduce microvascular complications, based on long-term follow-up showing persistent benefits decades after intensive control, with a "legacy effect" producing long-term reductions in MI and all-cause mortality 5, 6
The Endocrine Society suggests avoiding aggressive near-normal A1C targets (<6.5%) in patients with long-standing diabetes, established cardiovascular disease, history of severe hypoglycemia, or advanced age or frailty, as the ACCORD trial showed increased mortality with intensive glycemic control in these high-risk populations 5, 6

The American College of Cardiology recommends adding a GLP-1 receptor agonist or SGLT2 inhibitor immediately, independent of A1C, in patients with established ASCVD, CKD, or heart failure, as these agents provide mortality reduction and morbidity benefits 1, 2
The American Diabetes Association suggests considering a GLP-1 receptor agonist or SGLT2 inhibitor as first-line therapy in patients with high cardiovascular risk, as these agents provide cardiovascular benefit and reduce the risk of major adverse cardiovascular events 1, 3

The American Heart Association notes that when combining GLP-1 receptor agonists or SGLT2 inhibitors with insulin or sulfonylureas, basal insulin should be reduced by 20% immediately to prevent hypoglycemia, and sulfonylurea doses should be discontinued or reduced by 50% when initiating these agents 2
The Endocrine Society warns that GLP-1 receptor agonists are contraindicated in patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN2), and in patients with a history of severe hypersensitivity reaction 2, 3

The American College of Cardiology advises against delaying GLP-1 receptor agonist or SGLT2 inhibitor initiation until multiple oral agents have failed, as the cardiovascular and renal benefits accrue over time, and waiting for "treatment failure" means missing years of protective effects 1
The American Diabetes Association suggests not assuming metformin must be continued when adding GLP-1 receptor agonists or SGLT2 inhibitors, as these agents provide cardiovascular benefit independent of metformin use, and the combination may not be necessary if glucose targets are met 1